Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Clinical Diagnosis Track

Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated multi-parametric MRI of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer

Martin Freitag, Claudia Kesch, Jens Cardinale, Heinz Schlemmer, Uwe Haberkorn, Klaus Kopka and Frederik Giesel
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 538;
Martin Freitag
1German Cancer Research Center (DKFZ) Heidelberg Germany
2German Cancer Research Center (DKFZ) Heidelberg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Kesch
6Urology University of Heidelberg Heidelberg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jens Cardinale
1German Cancer Research Center (DKFZ) Heidelberg Germany
2German Cancer Research Center (DKFZ) Heidelberg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heinz Schlemmer
1German Cancer Research Center (DKFZ) Heidelberg Germany
2German Cancer Research Center (DKFZ) Heidelberg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Haberkorn
4University of Heidelberg Heidelberg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Kopka
3Division of Radiopharmaceutical Chemistry German Cancer Research Center (DKFZ) Heidelberg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik Giesel
5Nuclear Medicine University of Heidelberg Heidelberg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 58 no. supplement 1 538

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online May 24, 2017.

Copyright & Usage 
© 2017

Author Information

  1. Martin Freitag1,2,
  2. Claudia Kesch6,
  3. Jens Cardinale1,2,
  4. Heinz Schlemmer1,2,
  5. Uwe Haberkorn4,
  6. Klaus Kopka3 and
  7. Frederik Giesel5
  1. 1German Cancer Research Center (DKFZ) Heidelberg Germany
  2. 2German Cancer Research Center (DKFZ) Heidelberg Germany
  3. 3Division of Radiopharmaceutical Chemistry German Cancer Research Center (DKFZ) Heidelberg Germany
  4. 4University of Heidelberg Heidelberg Germany
  5. 5Nuclear Medicine University of Heidelberg Heidelberg Germany
  6. 6Urology University of Heidelberg Heidelberg Germany

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: May 2017 to April 2025

AbstractFullPdf
May 20171300
Jun 201710300
Jul 20173000
Aug 20173400
Sep 20174600
Oct 20174500
Nov 20171600
Dec 20171500
Jan 20181400
Feb 20182500
Mar 20182500
Apr 20182200
May 20181800
Jun 2018700
Jul 2018800
Aug 2018100
Sep 2018300
Oct 2018400
Nov 2018500
Dec 2018600
Jan 20191100
Feb 20191700
Mar 2019300
Apr 2019500
May 2019700
Jun 2019600
Jul 20191200
Aug 2019700
Sep 20191200
Oct 20191000
Nov 2019500
Dec 2019300
Jan 2020600
Feb 20201000
Mar 20202600
Apr 20201600
May 20201500
Jun 2020700
Jul 20201600
Aug 20201400
Sep 20202300
Oct 20201600
Nov 20202500
Dec 20201300
Jan 2021700
Feb 20211200
Mar 20211300
Apr 2021900
May 2021700
Jun 2021300
Jul 20211600
Aug 20213400
Sep 20211200
Oct 20211300
Nov 20216900
Dec 20214400
Jan 20227200
Feb 20222900
Mar 20223200
Apr 20223000
May 20223400
Jun 2022300
Jul 2022400
Aug 2022300
Sep 2022300
Oct 2022700
Nov 2022900
Dec 2022400
Jan 20231300
Feb 2023200
Mar 2023100
Apr 2023800
May 2023200
Jun 2023500
Jul 2023100
Aug 2023200
Sep 2023200
Oct 2023300
Nov 2023500
Dec 2023100
Jan 2024500
Feb 2024600
Mar 2024200
Apr 2024500
May 2024500
Jun 2024400
Jul 2024200
Aug 2024800
Sep 2024500
Oct 2024200
Nov 2024600
Dec 2024200
Jan 2025100
Feb 2025400
Mar 2025500
Apr 2025500
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 58, Issue supplement 1
May 1, 2017
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated multi-parametric MRI of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated multi-parametric MRI of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer
Martin Freitag, Claudia Kesch, Jens Cardinale, Heinz Schlemmer, Uwe Haberkorn, Klaus Kopka, Frederik Giesel
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 538;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated multi-parametric MRI of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer
Martin Freitag, Claudia Kesch, Jens Cardinale, Heinz Schlemmer, Uwe Haberkorn, Klaus Kopka, Frederik Giesel
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 538;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Clinical Diagnosis Track

  • Immunohistochemical analysis of Gastrin-Releasing-Peptide receptor (GRPr) and Prostate-Specific- Membrane Antigen (PSMA) in primary prostate cancer: comparison with radiolabeled GRPr antagonist (68Ga-RM2) PET/CT
  • Relationship between FDG PETCT imaging and CA 125 levels in treated patients with Ovarian cancers - Can FDG PETCT define and predict the disease burden in clinically suspected recurrence ?
  • Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of SUVmax
Show more Oncology, Clinical Diagnosis Track

Prostate I: Initial Staging

  • Ga-68 PSMA 11 PET/MRI in Patients with Newly Diagnosed Intermediate and High-Risk Prostate Cancers
  • Incremental value of 11C-acetate over 68Ga-PSMA PET/CT for diagnosis of primary prostate cancer patients with low-risk clinical factors
Show more Prostate I: Initial Staging

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire